Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators

Despite three decades of proven safety and effectiveness of hydroxyurea in modifying sickle cell disease (SCD), its accessibility is limited in Sub-Saharan Africa, which shares 75% of the world’s SCD burden. Therefore, it is time to explore the barriers and facilitators for manufacturing and importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mlyuka, Hamu J., Kilonzi, Manase, Mutagonda, Ritah F., Chirande, Lulu, Mikomangwa, Wigilya P., Myemba, David T., Sambayi, Godfrey, Mwakawanga, Dorkasi L., Ndunguru, Joyce, Jonathan, Agnes, Makani, Julie, Ruggajo, Paschal, Minja, Irene K., Balandya, Emmanuel, Kamuhabwa, Appolinary A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690851/
https://www.ncbi.nlm.nih.gov/pubmed/36360565
http://dx.doi.org/10.3390/healthcare10112223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690851/
https://www.ncbi.nlm.nih.gov/pubmed/36360565
http://dx.doi.org/10.3390/healthcare10112223

Ejemplares similares